<DOC>
	<DOCNO>NCT02294474</DOCNO>
	<brief_summary>Primary Objective : To demonstrate non-inferiority SAR342434 versus Humalog glycated hemoglobin A1c ( HbA1c ) change baseline Week 26 patient type 2 diabetes mellitus ( T2DM ) also use insulin glargine . Secondary Objectives : To assess immunogenicity SAR342434 Humalog term positive/negative status antibody titer baseline course study ; To assess relationship anti-insulin antibody efficacy safety . To assess efficacy SAR342434 Humalog : proportion patient reach target HbA1c &lt; 7.0 % ≤6.5 % , fast plasma glucose ( FPG ) self-measured plasma glucose ( SMPG ) profile , insulin dose . To assess safety SAR342434 Humalog .</brief_summary>
	<brief_title>Comparison SAR342434 Humalog Rapid Acting Insulin Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine</brief_title>
	<detailed_description>The study consist : 2 week screen period , 26-week treatment period , 1-day follow-up period . The maximum study duration 28 week per patient 1-day safety follow-up .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin , Short-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Patients T2DM diagnose least 12 month treat insulin glargine Humalog®/Liprolog® NovoLog®/NovoRapid® ( least 3 time daily , meal ) 6 month prior screen visit . Signed write informed consent . Exclusion criterion : At screen visit , age legal age adulthood . HbA1c &lt; 6.5 % &gt; 10.0 % screening . Diabetes T2DM . Pregnancy lactation . Women childbearing potential protect highly effective contraceptive method birth control . Use insulin pump 6 month screen visit . Use insulin insulin glargine Humalog NovoLog/NovoRapid 6 month prior screen visit . Liprolog® EU approve insulin lispro allow country market . Use Humalog/Liprolog Novolog/NovoRapid less 3 time daily , meal . Use noninjectable peptide ( eg , GLP1receptoragonists peptides ) 6 month prior screen visit . Body mass index ( BMI ) ≥40kg/m² screen visit . Hospitalization diabetic ketoacidosis last 6 month screen visit . Unstable proliferative diabetic retinopathy rapidly progressive diabetic retinopathy macular edema likely require treatment ( eg , laser , surgical treatment , injectable drug ) study period . The information intend contain consideration relevant patient 's potential participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>